Acquired Resistance to Antituberculosis Drugs in England, Wales, and Northern Ireland, 2000-2015

Overview

Journal Emerg Infect Dis

Specialty Infectious Diseases

Date 2018 Feb 21

PMID 29460735

Citations 10

Authors

Miranda G Loutet

Jennifer A Davidson

Tim Brown

Martin Dedicoat

H Lucy Thomas

Maeve K Lalor

Affiliations

Soon will be listed here.

Abstract

Among tuberculosis (TB) patients, acquired resistance to anti-TB drugs represents a failure in the treatment pathway. To improve diagnosis and care for patients with drug-resistant TB, we examined the epidemiology and risk factors associated with acquired drug resistance during 2000-2015 among TB patients in England, Wales, and Northern Ireland. We found acquired resistance in 0.2% (158/67,710) of patients with culture-confirmed TB. Using multivariate logistic regression, we identified the following factors associated with acquired drug resistance: having pulmonary disease; initial resistance to isoniazid, rifampin, or both; a previous TB episode; and being born in China or South Africa. Treatment outcomes were worse for patients with than without acquired resistance. Although acquired resistance is rare in the study area, certain patient groups are at higher risk. Identifying these patients and ensuring that adequate resources are available for treatment may prevent acquisition of resistance, thereby limiting transmission of drug-resistant strains of mycobacteria.

Citing Articles

Drug-resistant tuberculosis treatments, the case for a phase III platform trial.

Yates T, Barnes S, Dedicoat M, Kon O, Kunst H, Lipman M Bull World Health Organ. 2024; 102(9):657-664.

PMID: 39219765 PMC: 11362690. DOI: 10.2471/BLT.23.290948.

Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: a systematic review and meta-analysis.

Perumal R, Bionghi N, Nimmo C, Letsoalo M, Cummings M, Hopson M Eur Respir J. 2023; 62(6).

PMID: 37945030 PMC: 11035900. DOI: 10.1183/13993003.00639-2023.

Incidence and predictors of acquired resistance to second-line antituberculosis drugs during the course of multi-drug resistant tuberculosis treatment: protocol for a systematic review and meta-analysis.

Alemu A, Bitew Z, Diriba G, Gashu E, Seid G, Eshetu K BMJ Open. 2023; 13(4):e070143.

PMID: 37019479 PMC: 10083796. DOI: 10.1136/bmjopen-2022-070143.

Influence of COVID-19 for delaying the diagnosis and treatment of pulmonary tuberculosis-Tianjin, China.

Zhang G, Yu Y, Zhang W, Shang J, Chen S, Pang X Front Public Health. 2022; 10:937844.

PMID: 36530737 PMC: 9755169. DOI: 10.3389/fpubh.2022.937844.

Potential to Use Fingerprints for Monitoring Therapeutic Levels of Isoniazid and Treatment Adherence.

Ismail M, Costa C, Longman K, Chambers M, Menzies S, Bailey M ACS Omega. 2022; 7(17):15167-15173.

PMID: 35572755 PMC: 9089686. DOI: 10.1021/acsomega.2c01257.

References

Aldridge R, Shaji K, Hayward A, Abubakar I . Accuracy of Probabilistic Linkage Using the Enhanced Matching System for Public Health and Epidemiological Studies. PLoS One. 2015; 10(8):e0136179. PMC: 4547731. DOI: 10.1371/journal.pone.0136179. View

Gao J, Ma Y, Du J, Zhu G, Tan S, Fu Y . Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis. BMC Pulm Med. 2016; 16:26. PMC: 4743330. DOI: 10.1186/s12890-016-0187-3. View

Ershova J, Kurbatova E, Moonan P, Cegielski J . Mortality among tuberculosis patients with acquired resistance to second-line antituberculosis drugs--United States, 1993-2008. Clin Infect Dis. 2014; 59(4):465-72. PMC: 4784225. DOI: 10.1093/cid/ciu372. View

Walker T, Kohl T, Omar S, Hedge J, Del Ojo Elias C, Bradley P . Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis. 2015; 15(10):1193-1202. PMC: 4579482. DOI: 10.1016/S1473-3099(15)00062-6. View

Iseman M . Treatment of multidrug-resistant tuberculosis. N Engl J Med. 1993; 329(11):784-91. DOI: 10.1056/NEJM199309093291108. View

Smith C, Abubakar I, Thomas H, Anderson L, Lipman M, Reacher M . Incidence and risk factors for drug intolerance and association with incomplete treatment for tuberculosis: analysis of national case registers for England, Wales and Northern Ireland, 2001-2010. Thorax. 2013; 69(10):956-8. PMC: 4174126. DOI: 10.1136/thoraxjnl-2013-204503. View

Kibret K, Moges Y, Memiah P, Biadgilign S . Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies. Infect Dis Poverty. 2017; 6(1):7. PMC: 5240443. DOI: 10.1186/s40249-016-0214-x. View

Nikolayevskyy V, Hillemann D, Richter E, Ahmed N, van der Werf M, Kodmon C . External Quality Assessment for Tuberculosis Diagnosis and Drug Resistance in the European Union: A Five Year Multicentre Implementation Study. PLoS One. 2016; 11(4):e0152926. PMC: 4824391. DOI: 10.1371/journal.pone.0152926. View

Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rusch-Gerdes S, Willery E . Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol. 2006; 44(12):4498-510. PMC: 1698431. DOI: 10.1128/JCM.01392-06. View

10.

Yuen C, Kurbatova E, Click E, Cavanaugh J, Cegielski J . Association between Mycobacterium tuberculosis complex phylogenetic lineage and acquired drug resistance. PLoS One. 2013; 8(12):e83006. PMC: 3871645. DOI: 10.1371/journal.pone.0083006. View

11.

Cegielski J, Kurbatova E, Van Der Walt M, Brand J, Ershova J, Tupasi T . Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance. Clin Infect Dis. 2015; 62(4):418-430. PMC: 4725381. DOI: 10.1093/cid/civ910. View

12.

Gagneux S, Small P . Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis. 2007; 7(5):328-37. DOI: 10.1016/S1473-3099(07)70108-1. View

13.

Mathuria J, Samaria J, Srivastava G, Mathuria B, Ojha S, Anupurba S . Primary and acquired drug resistance patterns of Mycobacterium tuberculosis isolates in India: a multicenter study. J Infect Public Health. 2013; 6(6):456-64. DOI: 10.1016/j.jiph.2013.03.003. View

14.

Jeon C, Hwang S, Min J, Prevots D, Goldfeder L, Lee H . Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis. 2008; 46(1):42-9. DOI: 10.1086/524017. View

15.

Cegielski J, Dalton T, Yagui M, Wattanaamornkiet W, Volchenkov G, Via L . Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis. 2014; 59(8):1049-63. PMC: 4184341. DOI: 10.1093/cid/ciu572. View

16.

Smith S, Ershova J, Vlasova N, Nikishova E, Tarasova I, Eliseev P . Risk factors for acquisition of drug resistance during multidrug-resistant tuberculosis treatment, Arkhangelsk Oblast, Russia, 2005-2010. Emerg Infect Dis. 2015; 21(6):1002-11. PMC: 4451928. DOI: 10.3201/eid2106.141907. View

17.

Aung K, Van Deun A, Declercq E, Sarker M, Das P, Hossain M . Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis. 2014; 18(10):1180-7. DOI: 10.5588/ijtld.14.0100. View

18.

Ershova J, Kurbatova E, Moonan P, Cegielski J . Acquired resistance to second-line drugs among persons with tuberculosis in the United States. Clin Infect Dis. 2012; 55(12):1600-7. PMC: 4758461. DOI: 10.1093/cid/cis748. View

19.

Andrews J, Shah N, Weissman D, Moll A, Friedland G, Gandhi N . Predictors of multidrug- and extensively drug-resistant tuberculosis in a high HIV prevalence community. PLoS One. 2011; 5(12):e15735. PMC: 3012092. DOI: 10.1371/journal.pone.0015735. View

20.

Brown T, Nikolayevskyy V, Velji P, Drobniewski F . Associations between Mycobacterium tuberculosis strains and phenotypes. Emerg Infect Dis. 2010; 16(2):272-80. PMC: 2958017. DOI: 10.3201/eid1602.091032. View